AMO Pharma: Encouraging Phase II Results for Congenital and Juvenile Myotonic Trial.
AMO Pharma has announced results from its ongoing phase II study investigating two doses of tideglusib (AMO-02) in adults with congenital...
Muscle Owl Talks Ep46: Spinraza Approved for All Types of SMA by EMA (Europe)
On Friday we received the news that Spinraza - the latest (and first) treatment for spinal muscular atrophy - had been approved by the...
Muscle Owl Talks Ep40: Upcoming Treatments for MD Adults?
We continue to see a large increase in the number of drugs progressing through clinical trials and coming to market. Will this translate...
Marathon Sells DMD Drug Deflazacort to PTC Following Price Hike Criticism
Following widespread criticism for its price hike in its recently purchased Duchenne drug, Deflazacort, Marathon have agreed terms to...
Resolaris Granted Orphan Drug Designation for LGMD & FSHMD
The European Medicines Agency has granted Orphan Drug Designation to Resolaris (ATYR1940) for the treatment of all types of limb girdle...
